Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: potentially increased levels of dihydroergotamine
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Increased risk of dihydroergotamine adverse effects
Management
Use alternative agents
Info Source
